$Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib$
QR Code

QR Code

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib

R Donald HarveyPhase 1 Clinical Trials Section, Winship Cancer Institute of Emory University, Atlanta, GA, USAAbstract: Carfilzomib, a selective proteasome inhibitor approved in the USA in 2012, is a single agent for relapsed and refractory multiple myeloma. Carfilzomib is administered as a 2&n...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Harvey RD
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2014
Sujets:	Therapeutics. Pharmacology RM1-950
Accès en ligne:	https://doaj.org/article/e61e73945e8e499f9a1d996fbc7afd8c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
par: Chetan Rathi, et autres
Publié: (2021)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
par: Gupta VA, et autres
Publié: (2013)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
par: Nooka A, et autres
Publié: (2013)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
par: Li Y, et autres
Publié: (2017)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
par: Shansa Pranami E. Jayaweera, et autres
Publié: (2021)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
par: Joseph NS, et autres
Publié: (2021)

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
par: Kimiko Koiwai, et autres
Publié: (2021)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
par: Bhutani D, et autres
Publié: (2017)

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
par: Tandon N, et autres
Publié: (2016)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
par: Slobodan M Jankovic
Publié: (2010)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS
par: Mehmut TURGUT, et autres
Publié: (2021)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
par: Han N, et autres
Publié: (2021)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
par: Hayato Katsuno, et autres
Publié: (2021)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
par: Mary H. Young, et autres
Publié: (2021)

Differential renal adverse effects of ibuprofen and indomethacin in preterm infants: a review
par: Pacifici GM
Publié: (2014)

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab
par: Masood Khaksar Toroghi, et autres
Publié: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
par: Xiaoyin Bai, et autres
Publié: (2021)

Translation, Cross-Cultural Adaptation, and Measurement Properties of the Portuguese Version of the Global Trigger Tool for Adverse Events
par: Pierdevara L, et autres
Publié: (2020)

Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
par: Ali Zahit Bolaman, et autres
Publié: (2021)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
par: Tran JQ, et autres
Publié: (2016)

Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers
par: Kawabata M, et autres
Publié: (2015)

Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India
par: Chetak Kadabasal Basavaraja, et autres
Publié: (2021)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
par: Cui Y, et autres
Publié: (2013)

Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
par: Matsumoto T
Publié: (2014)

Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)
par: Takehiro Kawashiri, et autres
Publié: (2021)

Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies
par: Yildiz H, et autres
Publié: (2021)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
par: Cui Y, et autres
Publié: (2014)

Managing refractory cryoglobulinemic vasculitis: challenges and solutions
par: Ostojic P, et autres
Publié: (2017)

Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials
par: Yali Tao, et autres
Publié: (2021)

Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways
par: Arnold P, et autres
Publié: (2014)

Risk factors for immune-related adverse events: what have we learned and what lies ahead?
par: Xiaoyan Liu, et autres
Publié: (2021)

Naloxone as a trigger to identify opioid-related adverse events in pediatric intensive care units
par: Haline Ogata, et autres
Publié: (2020)

Patients in chronic prednisone use in a Brazilian municipality: are potential adverse events being monitored?
par: Virgínia M. Bolina, et autres
Publié: (2020)

Adverse drug events: description of an active search process in a teaching hospital of the Sentinela Network
par: Wanessa S. NOGUEIRA, et autres
Publié: (2021)

Tuberculosis Relapse in the Epididymis After the Completion of Nine Months of Anti-Tuberculosis Chemotherapy in a Patient with Poorly Controlled Diabetes Mellitus
par: Ichikawa C, et autres
Publié: (2021)

In Reference to Risk Perception of Septic Shock with Multiple Organ Failure Due to Acute Exacerbation of an Infectious Dental Disease [Letter]
par: Baba Y, et autres
Publié: (2021)

Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis
par: Yanhong Yao, et autres
Publié: (2021)

Risk Factors for Perioperative Respiratory Adverse Events in Children with Recent Upper Respiratory Tract Infection: A Single-Center-Based Retrospective Study
par: Lee HJ, et autres
Publié: (2020)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
par: Tahaineh L, et autres
Publié: (2018)

Alemtuzumab in the treatment of multiple sclerosis
par: Fernandez Ó
Publié: (2014)